Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 10, Issue 2, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-02-14
DOI
10.1038/s41408-020-0273-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
- (2019) Shaji K. Kumar et al. LEUKEMIA
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement
- (2018) Wilson I. Gonsalves et al. BONE MARROW TRANSPLANTATION
- Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma
- (2018) Jennifer Huang et al. BONE MARROW TRANSPLANTATION
- Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma
- (2018) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study
- (2018) Kara-Louise Royle et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma
- (2018) Jesús F. San-Miguel et al. HAEMATOLOGICA
- Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis
- (2018) Chiara Cerrato et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018
- (2018) Shaji K. Kumar et al. Journal of the National Comprehensive Cancer Network
- Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
- (2018) Heinz Ludwig et al. LEUKEMIA
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
- (2018) Elizabeth Dianne Pulte et al. ONCOLOGIST
- A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma
- (2018) Jesús F. San-Miguel et al. HAEMATOLOGICA
- Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry
- (2018) Rafat Abonour et al. ANNALS OF HEMATOLOGY
- Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry
- (2018) Robert M. Rifkin et al. CLINICAL THERAPEUTICS
- Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis
- (2018) Manuela Gambella et al. CANCER
- All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
- (2018) Meletios A. Dimopoulos et al. EUROPEAN JOURNAL OF CANCER
- Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
- (2018) Meletios A Dimopoulos et al. LANCET
- Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
- (2018) Graham H Jackson et al. LANCET ONCOLOGY
- Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer?
- (2018) Thomas Wilke et al. Patient Preference and Adherence
- Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial
- (2018) Niels WCJ van de Donk et al. Lancet Haematology
- From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
- (2017) Francesca Gay et al. HAEMATOLOGICA
- Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
- (2017) Juan-Jose Lahuerta et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
- (2017) Philip L. McCarthy et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
- (2017) Brian G M Durie et al. LANCET
- Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
- (2017) S Bringhen et al. LEUKEMIA
- Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation
- (2017) R Chakraborty et al. LEUKEMIA
- Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial
- (2017) N J Bahlis et al. LEUKEMIA
- Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial
- (2017) L Rosiñol et al. LEUKEMIA
- Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial
- (2017) H Goldschmidt et al. LEUKEMIA
- Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone
- (2017) Dan T. Vogl et al. LEUKEMIA & LYMPHOMA
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
- (2017) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment Satisfaction and Burden of Illness With Oral Vs Injectable Multiple Myeloma Therapy in Patients with Newly Diagnosed Disease (NDMM)
- (2017) D Romanus et al. VALUE IN HEALTH
- From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
- (2017) Francesca Gay et al. HAEMATOLOGICA
- Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response
- (2017) Nicola Lehners et al. Cancer Medicine
- Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial
- (2017) Sarah A Holstein et al. Lancet Haematology
- Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma
- (2016) Sonja Zweegman et al. BLOOD
- Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma
- (2016) Valeria Magarotto et al. BLOOD
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
- (2016) P. Sonneveld et al. BLOOD
- Multiple myeloma: practice patterns across Europe
- (2016) Marc S. Raab et al. BRITISH JOURNAL OF HAEMATOLOGY
- Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma
- (2015) A. K. Stewart et al. BLOOD
- Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide
- (2015) M. Delforge et al. HAEMATOLOGICA
- Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma
- (2015) M. A. Dimopoulos et al. HAEMATOLOGICA
- Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens
- (2015) Ruben Niesvizky et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
- (2015) Francesca Gay et al. LANCET ONCOLOGY
- Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life
- (2015) R. Baz et al. SUPPORTIVE CARE IN CANCER
- Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide
- (2015) M. Delforge et al. HAEMATOLOGICA
- Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma
- (2015) M. A. Dimopoulos et al. HAEMATOLOGICA
- GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?
- (2014) M.-V. Mateos et al. BLOOD
- International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation
- (2014) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
- (2014) Shaji K Kumar et al. LANCET ONCOLOGY
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
- (2014) Lotfi Benboubker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
- (2014) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial
- (2013) A. K. Stewart et al. BLOOD
- Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment
- (2013) G. J. Morgan et al. CLINICAL CANCER RESEARCH
- Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
- (2013) A K Nooka et al. LEUKEMIA
- Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial
- (2012) M.-V. Mateos et al. BLOOD
- IMWG consensus on maintenance therapy in multiple myeloma
- (2012) H. Ludwig et al. BLOOD
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
- (2012) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
- (2012) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis
- (2011) G. J. Morgan et al. BLOOD
- Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
- (2010) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More